Parkinson DiseaseNCT07207096
Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerative Disease (NDD) Clinic.
An observational study of Parkinson Disease and Parkinsonism, run by St. Mary's University, Twickenham at 1 site in United Kingdom.
Trial summary
When the charity Homeopathy UK launched a new London based charitable clinic for Neurodegenerative Diseases (NDD), including Parkinson's Disease (PD), it was considered important to document patient's experiences of a high-quality complementary medicine clinic, to enable a greater understanding of the role of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson Disease, Parkinsonism
- What is being tested?
- complementary medicine
- How many people
- 100 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 19 Sep 2025to 31 Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Consecutive patients who book an appointment for complementary therapy in the NDD clinic, and report a diagnosis of PD.
Inclusion Criteria: A diagnosis of Parkinson's Disease (self-reported), and Parkinsonism from any causes (patients may have co-existing other health conditions)
Exclusion Criteria: Patients requiring acute medical assessment and management, (as this is beyond the scope of this clinic service) Patients with any other NDD condition Patients without a diagnosis of PD/Parkinsonism. E.g. those at risk of PD such as through a family history (patients in this category may receive treatment at the clinic but are not included in the Observational Case series.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Yubraj Sharma, MD contact
United Kingdom1 site, 1 recruiting
- Recruiting
Feldy Community Centre
London, EX14 0XA
Androulla Pillos Smith, +44 7951788683 ext. 110, androulla@homeopathy-uk.org
Monica Price, 020 36405903, Monica@homeopathy-uk.org
About this study
When the charity Homeopathy UK launched a new London based charitable clinic for Neurodegenerative Diseases (NDD), including Parkinson's Disease (PD), it was considered important to document patient's experiences of a high-quality complementary medicine clinic, to enable a greater understanding of the role of complementary medicine for PD.
Routine clinical data, including a couple of questionnaires, is collected from consecutive patients with PD seen in the NDD clinic. Treatments provided are complementary to patients' usual medical treatment, and include homeopathy, herbalism, hypnosis, and healing. Patients may also be provided with self-help advice for lifestyle changes, mindfulness or meditation techniques, and dietary advice, as indicated for complementary therapy management of their condition. Consultations take place approximately every 3 months and patients complete questionnaires at the time of each consultation.
Read the detailed description
Clinical research documenting the effectiveness of complementary medicine for PD is long overdue. Despite high rates of utilization, data on efficacy is generally limited, restricting physicians in providing guidance to interested patients (Bega, 2014).
When the charity Homeopathy UK launched a new London based charitable clinic specifically for NDD, including Parkinson's Disease, it was considered important to document patient's experiences of a high-quality complementary medicine clinic, to enable a greater understanding of the role of complementary medicine for PD.
This is an observational case series with no deviation from routine clinical practice. Routine clinical data is collected from consecutive PD patients seen in the NDD clinic. Patients complete questionnaires regardless of whether they take part in the research. Consultations take place approximately every 3 months (time between appointments may be reduced to 1 month for those patients needing more frequent management, or extended to 6 months for those who require less management). For those patients who are unable to travel, e.g. due to neurological disability and/or long distance away, the 1.5 hour appointment is provided as a remote clinic link using a secure zoom platform.
Treatments provided are complementary, i.e. provided alongside patients' usual medical treatment. Complementary therapies provided include homeopathy, herbalism, hypnosis, and healing. Patients may also be provided with self-help advice for lifestyle changes, mindfulness or meditation techniques, and dietary advice, as indicated for complementary therapy management of their condition.
Two validated outcome measures are used at each clinic visit. Both measures are used both for clinical assessment and the Observational Case Series.
- The MDS-sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) which has four parts. The majority of the MDS-UPDRS is completed by the clinic doctor, however Part IB is completed independently by the patient with or without the aid of the caregiver.
- Measure Your Own Medical Outcome Profile (MYMOP) is a patient generated outcome measure consisting of 4 self-chosen items measured using a likert type scale of 0 (as good as it could be) to 6 (as bad as it could be): two symptoms considered most bothersome, an activity which the condition limits participation in, and wellbeing.
It is a validated, personalized measure allowing patients to select their key concerns, and considered appropriate to capture the non-specific effects of complementary medicine.
We aim to collect routine data from 100+ consecutive PD patients. Patients are recruited to the observational study after they have booked an appointment for complementary therapy in the NDD clinic, and report a diagnosis of PD. Patients are informed of the study then and also during their initial clinic appointment. They are informed there is no compulsion to enrol into the study, and they can continue being assessed and treated at the clinic even if they remain outside the study, and that there is no difference in the standard of their treatment.
Bega, D., Gonzalez-Latapi, P., Zadikoff, C., \& Simuni, T. (2014). A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease. Current treatment options in neurology, 16, 1-19.
- Conditions
- Parkinson Disease, Parkinsonism
- Being tested
- complementary medicine
- Keywords
- homeopathy, herbalism, hypnosis, healing, complementary medicine, lifestyle, self-help, mindfulness, Parkinson Disease
- Medical subject headings
- Parkinson Disease, Parkinsonian Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
complementary medicineCombination product
Also called homeopathy, herbalism, hypnosis, healing
Complementary therapies provided include homeopathy, herbalism, hypnosis, and healing. Patients may also be provided with self-help advice for lifestyle changes, mindfulness or meditation techniques, and dietary advice, as indicated for complementary therapy management of their condition.
What is being measured
The primary outcome is the main question the study is designed to answer.
The MDS-sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
The MDS-UPDRS has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination) and Part IV (motor complications).
The majority of the MDS-UPDRS is completed by the clinic doctor. However Part IB is completed independently by the patient with or without the aid of the caregiver.
Measured: At each consultation (approximately every 3 months)
Measure Your Own Medical Outcome Profile (MYMOP)
MYMOP is a patient generated outcome measure consisting of 4 self-chosen items measured using a likert type scale of 0 (as good as it could be) to 6 (as bad as it could be): two symptoms considered most bothersome, an activity which the condition limits participation in, and wellbeing.
It is a validated, personalized measure allowing patients to select their key concerns, and considered appropriate to capture the non-specific effects of complementary medicine.
Measured: At each consultation (approximately every 3 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Oct 2025
- Study start19 Sep 2025
- Primary completion31 Aug 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- St. Mary's University, Twickenham
- Sponsor type
- University, hospital or other
- Collaborators
- Faculty of Homeopathy, Homeopathy UK
- Responsible party
- Principal investigator, Philippa Fibert, St. Mary's University, Twickenham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07207096
- Sponsor's protocol ID
- SMU_ETHICS_2024_25_1128
- Status last verified
- Sep 2025
- First submitted
- 26 Sep 2025
- Last updated
- 3 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Anonymised data will be kept for a period of ten years on the St Mary's University Open Research Archive, which is a condition of St Mary's University
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerative Disease (NDD) Clinic.
- ClinicalTrials.gov ID
- NCT07207096
- Acronym / sponsor ID
- SMU_ETHICS_2024_25_1128
- Conditions
- Parkinson Disease, Parkinsonism
- Keywords
- homeopathy, herbalism, hypnosis, healing, complementary medicine, lifestyle, self-help, mindfulness
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- St. Mary's University, TwickenhamUniversity, hospital or other
- Collaborators
- Faculty of Homeopathy, Homeopathy UK
- Study start
- 19 Sep 2025 (actual)
- Primary completion
- 31 Aug 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 3 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
When the charity Homeopathy UK launched a new London based charitable clinic for Neurodegenerative Diseases (NDD), including Parkinson's Disease (PD), it was considered important to document patient's experiences of a high-quality complementary medicine clinic, to enable a greater understanding of the role of complementary medicine for PD.
Routine clinical data, including a couple of questionnaires, is collected from consecutive patients with PD seen in the NDD clinic. Treatments provided are complementary to patients' usual medical treatment, and include homeopathy, herbalism, hypnosis, and healing. Patients may also be provided with self-help advice for lifestyle changes, mindfulness or meditation techniques, and dietary advice, as indicated for complementary therapy management of their condition. Consultations take place approximately every 3 months and patients complete questionnaires at the time of each consultation.
Detailed description
Clinical research documenting the effectiveness of complementary medicine for PD is long overdue. Despite high rates of utilization, data on efficacy is generally limited, restricting physicians in providing guidance to interested patients (Bega, 2014).
When the charity Homeopathy UK launched a new London based charitable clinic specifically for NDD, including Parkinson's Disease, it was considered important to document patient's experiences of a high-quality complementary medicine clinic, to enable a greater understanding of the role of complementary medicine for PD.
This is an observational case series with no deviation from routine clinical practice. Routine clinical data is collected from consecutive PD patients seen in the NDD clinic. Patients complete questionnaires regardless of whether they take part in the research. Consultations take place approximately every 3 months (time between appointments may be reduced to 1 month for those patients needing more frequent management, or extended to 6 months for those who require less management). For those patients who are unable to travel, e.g. due to neurological disability and/or long distance away, the 1.5 hour appointment is provided as a remote clinic link using a secure zoom platform.
Treatments provided are complementary, i.e. provided alongside patients' usual medical treatment. Complementary therapies provided include homeopathy, herbalism, hypnosis, and healing. Patients may also be provided with self-help advice for lifestyle changes, mindfulness or meditation techniques, and dietary advice, as indicated for complementary therapy management of their condition.
Two validated outcome measures are used at each clinic visit. Both measures are used both for clinical assessment and the Observational Case Series.
- The MDS-sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) which has four parts. The majority of the MDS-UPDRS is completed by the clinic doctor, however Part IB is completed independently by the patient with or without the aid of the caregiver.
- Measure Your Own Medical Outcome Profile (MYMOP) is a patient generated outcome measure consisting of 4 self-chosen items measured using a likert type scale of 0 (as good as it could be) to 6 (as bad as it could be): two symptoms considered most bothersome, an activity which the condition limits participation in, and wellbeing.
It is a validated, personalized measure allowing patients to select their key concerns, and considered appropriate to capture the non-specific effects of complementary medicine.
We aim to collect routine data from 100+ consecutive PD patients. Patients are recruited to the observational study after they have booked an appointment for complementary therapy in the NDD clinic, and report a diagnosis of PD. Patients are informed of the study then and also during their initial clinic appointment. They are informed there is no compulsion to enrol into the study, and they can continue being assessed and treated at the clinic even if they remain outside the study, and that there is no difference in the standard of their treatment.
Bega, D., Gonzalez-Latapi, P., Zadikoff, C., \& Simuni, T. (2014). A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease. Current treatment options in neurology, 16, 1-19.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Consecutive patients who book an appointment for complementary therapy in the NDD clinic, and report a diagnosis of PD.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| complementary medicineAlso: homeopathy, herbalism, hypnosis, healingComplementary therapies provided include homeopathy, herbalism, hypnosis, and healing. Patients may also be provided with self-help advice for lifestyle changes, mindfulness or meditation techniques, and dietary advice, as indicated for complementary therapy management of their condition. | Combination product | – |
Primary outcome
The MDS-sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Time frame: At each consultation (approximately every 3 months)
The MDS-UPDRS has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination) and Part IV (motor complications). The majority of the MDS-UPDRS is completed by the clinic doctor. However Part IB is completed independently by the patient with or without the aid of the caregiver.
Measure Your Own Medical Outcome Profile (MYMOP)
Time frame: At each consultation (approximately every 3 months)
MYMOP is a patient generated outcome measure consisting of 4 self-chosen items measured using a likert type scale of 0 (as good as it could be) to 6 (as bad as it could be): two symptoms considered most bothersome, an activity which the condition limits participation in, and wellbeing. It is a validated, personalized measure allowing patients to select their key concerns, and considered appropriate to capture the non-specific effects of complementary medicine.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2025.
- Individual participant dataSharing planned: No. Anonymised data will be kept for a period of ten years on the St Mary's University Open Research Archive, which is a condition of St Mary's University
Related trials for Parkinson Disease
Active, not recruitingPhase 3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Carcinoma, Renal Cell
Not yet recruiting
The Effects of Ischemic Conditioning in Individuals With Parkinson's Disease
Parkinson Disease
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yubraj Sharma, MD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease and Parkinsonism, run by St. Mary's University, Twickenham at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Philippa Fibert, PhD (+44 7543345046, philippa.fibert@stmarys.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The MDS-sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (time frame: At each consultation (approximately every 3 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2025.